Nathan Campbell, Director of Clinical Services speaks about Cancer Genetics’ Biorepository capability and how having access to samples genomic data is important.
As a clinical trial progresses and a more diverse patient population is recruited, variations in a drug’s efficacy and safety can start to arise. Unexpected adverse events can potentially kill a drug at any phase of a clinical trial.
At Cancer Genetics, we understand it is critical for investigators to be able to go back and retrospectively evaluate the underlying genomic cause of these events. Because we offer biorepository storage and clinical testing services, we make it easy to go back and find those answers.
By managing both your sample and testing we can reduce complexity of Clinical Trials and help get your drug to market.
